Elutia Inc. Class A Common Stock
ELUTElutia Inc. Class A (ELUT) is a healthcare company focused on developing innovative treatments and solutions in the field of specialty pharmaceuticals. The company emphasizes research and development to address unmet medical needs and improve patient outcomes.
Company News
Elutia sold its BioEnvelope business to Boston Scientific for $88 million, allowing the company to focus on developing NXT-41x, a biomatrix technology for breast reconstruction with potential to address serious surgical complications.
BRC, Costamare and Elutia have been highlighted in this Screen of The Week article.
BRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company’s Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants...
EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market
